natgillin/translations-raw huggingface dataset:
P-value &lt; 0.0001 for mean decrease in HIV-1 RNA; P-value = 0.0006 for mean change in CD4 cell count.
P-vrijednost &lt; 0,0001 za prosječno smanjenje HIV-1 RNK; P-vrijednost = 0,0006 za prosječnu promjenu broja CD4 stanica.
p-value &lt; 0.0001 versus placebo + oral glucose-lowering medicinal product(s)
bo + peroralni lijek/ovi za snižavanje razine glukoze
p-value based on the log-rank test stratified by B2 microglobulins ( &lt; 3.5 mg/L versus ≥ 3.5 mg/L), number of prior lines of therapy (1 versus 2 or 3), and prior immunomodulatory therapy (no versus prior thalidomide only versus other).
p-vrijednost na temelju log-rang testa stratificiranog prema B2 mikroglobulinima ( &lt; 3,5 mg/l naspram ≥ 3,5 mg/l), broju prethodnih linija terapije (1 naspram 2 ili 3) i prethodnoj imunomodulacijskoj terapiji (bez terapije naspram prethodno samog talidomida naspram ostaloga).
p-values were &lt; 0.001 for both mTSS and erosion score and ≤ 0.01 for JSN score.
p-vrijednosti bile su &lt; 0,001 za oba, mTSS zbroj i zbroj erozija te ≤ 0,01 za JSN zbroj.
P &lt; 0.0001
p &lt; 0,0001
P &lt; 0.001 in favour of tacrolimus ointment 0.1% (adults) and 0.03% (children) for the primary and key secondary endpoints
P &lt; 0,001 u korist masti s 0,1% takrolimusa (odrasli) i 0,03% takrolimusa (djeca) za primarne i ključne sekundarne ishode
p &lt; 0.001, Fischer’s exact test
p &lt; 0,001, Fischerov egzaktni test
PAA and PBA represented minor urinary metabolites, each accounting for &lt; 1% of the administered dose of PBA.
PAA i PBA predstavljali su manje metabolite u mokraći, a na svaki je otpadalo &lt; 1% primijenjene doze PBA.
Paediatric Crohn's disease patients &lt; 40 kg:
Crohnova bolest u djece tjelesne težine &lt; 40 kg:
Paediatric exposure to fluticasone furoate in safety and efficacy studies in seasonal and perennial allergic rhinitis included 243 patients 12 to &lt; 18 years, 790 patients 6 to &lt; 12 years and 241 patients 2 to &lt; 6 years.
U ispitivanjima sigurnosti i djelotvornosti u pedijatrijskih bolesnika sa sezonskim i cjelogodišnjim alergijskim rinitisom flutikazonfuroatu je bilo izloženo 243 bolesnika u dobi od 12 do &lt; 18 godina, 790 bolesnika u dobi od 6 do &lt; 12 godina te 241 bolesnik u dobi od 2 do &lt; 6 godina.
Paediatric patients &lt; 1 year of age might be more prone to liver injury (see section 4.8).
Pedijatrijski bolesnici u dobi do 1 godine mogu biti skloniji oštećenju jetre (vidjeti dio 4.8).
Paediatric patients: A total of 26 paediatric patients of age &lt; 18 years with either chronic phase CML (n = 11) or CML in blast crisis or Ph+ acute leukaemias (n = 15) were enrolled in a dose-escalation phase I trial.
Pedijatrijski bolesnici: u ispitivanje faze I s povišenjem doze, uključeno je ukupno 26 pedijatrijskih bolesnika u dobi &lt; 18 godina bilo s kroničnom fazom KML-a (n=11), bilo s KML-om u blastičnoj krizi ili Ph+ akutnim leukemijama (n=15).
Paediatric patients: A total of 26 paediatric patients of age &lt; 18 years with either chronic phase CML (n=11) or CML in blast crisis or Ph+ acute leukaemias (n=15) were enrolled in a dose-escalation phase I trial.
Pedijatrijski bolesnici: u ispitivanje faze I s povišenjem doze, uključeno je ukupno 26 pedijatrijskih bolesnika u dobi &lt; 18 godina bilo s kroničnom fazom KML-a (n=11), bilo s KML-om u blastičnoj krizi ili Ph+ akutnim leukemijama (n=15).
Paediatric population (2 months to &lt; 18 years of age)
Pedijatrijska populacija (u dobi od 2 mjeseca do &lt; 18 godina)
Paediatric population ( &lt; 18 years old)
Pedijatrijska populacija ( &lt; 18 godina starosti)
Paediatric population ( &lt; 18 years old)
Pedijatrijska populacija ( &lt; 18 godina)
Paediatric population ( &lt; 18 years)
Pedijatrijska populacija ( &lt; 18 godina)
Paediatric population (children &lt; 9 years of age)
Pedijatrijska populacija (djeca u dobi od &lt; 9 godina)
Paediatric population (children &lt; 9 years of age)
Pedijatrijska populacija (djeca &lt; 9 godina)
Paediatric population &lt; 2 years
Pedijatrijska populacija u dobi od &lt; 2 godine
Paediatric population &lt; 2 years
Pedijatrijska populacija &lt; 2 godine
Paediatric population – children aged &lt; 3 years
Pedijatrijska populacija – djeca mlađa od 3 godine
Paediatric population: A lower rate of virologic response (HBV DNA &lt; 50 IU/ml) was observed in paediatric patients with baseline HBV DNA ≥ 8.0 log10 IU/ml (see section 5.1).
Pedijatrijska populacija: primijećena je niža stopa virološkog odgovora (HBV DNK &lt; 50 IU/ml) u pedijatrijskih bolesnika čija je početna vrijednost HBV DNK bila ≥ 8,0 log10 IU/ml (vidjeti dio 5.1).
Paediatric population: Study 189 is an ongoing study of the efficacy and safety of entecavir among 180 nucleoside-treatment-naïve children and adolescents from 2 to &lt; 18 years of age with HBeAg- positive chronic hepatitis B infection, compensated liver disease, and elevated ALT.
Pedijatrijska populacija: U ispitivanju 189, koje je još u tijeku, ispituje se djelotvornost i sigurnost entekavira u 180 djece i adolescenata u dobi od 2 do &lt; 18 godina s HBeAg pozitivnom kroničnom infekcijom hepatitisom B, kompenziranom bolešću jetre i povišenim razinama ALT-a, koji prethodno nisu bili liječeni analozima nukleozida.
Paediatric population: The pharmacokinetic parameters of ranolazine have not been studied in the paediatric population ( &lt; 18 years).
Pedijatrijska populacija: Parametri farmakokinetike ranolazina nisu istraživani u pedijatrijskoj populaciji ( &lt; 18 godina).
Paediatric population &lt; 12 years of age
Pedijatrijska populacija u dobi od &lt; 12 godina
Pain as assessed by the Total Back Pain and Nocturnal Back Pain VAS, and disease activity as measured by ASDAS-C also showed statistically significant improvement from baseline to week 16 in patients treated with Simponi 50 mg compared to placebo (p &lt; 0.0001).
Bol procijenjena pomoću VAS za bol u cijelim leđima i noćnu bol u leđima i aktivnost bolesti mjerena pomoću ASDAS-C pokazali su statistički značajno poboljšanje od početka do 16. tjedna u bolesnika liječenih lijekom Simponi u dozi od 50 mg u usporedbi s placebom (p &lt; 0,0001).
Pain in extremity (G3/4: &lt; 1%); Back pain (G3/4: 1%)
bol u udovima (G3/4: &lt; 1%), bol u leđima (G3/4: 1%)
Pain in extremity (G3/4: &lt; 1%); Back pain (G3/4: 1%)
bol u udovima (G3/4: &lt; 1%); bol u leđima (G3/4: 1%)
Pain, redness, swelling at the injection site, fever 38°C rectally (age &lt; 2 years)
bol, crvenilo, oticanje na mjestu injiciranja, vrućica 38°C rektalno (dob &lt; 2 godine)
Palmar-plantar erythrodysesthesia [PPE] was also common ( &gt; 25%) when lapatinib was administered in combination with capecitabine.
Palmarno-plantarna eritrodizestezija bila je česta ( &gt; 25%) i pri primjeni kombinacije lapatiniba i kapecitabina.
Pancreas survival at 1 year was significantly superior with tacrolimus: 91.3% versus 74.5% with ciclosporin (p &lt; 0.0005), whereas renal graft survival was similar in both groups.
Preživljenje gušterače nakon 1 godine bilo je značajno više uz takrolimus: 91,3% nasuprot 74,5% uz ciklosporin (p &lt; 0,0005), dok je preživljenje bubrežnog presatka bilo slično u obje skupine.
Pancreatitis has been observed uncommonly ( &lt; 1%) in patients receiving sunitinib for GIST or MRCC.
U bolesnika liječenih sunitinibom zbog GIST-a ili MRCC-a pankreatitis je zabilježen manje često ( &lt; 1%).
Pancreatitis has been reported in &lt; 1% of dabrafenib-treated subjects as monotherapy and in combination with trametinib.
Pankreatitis je zabilježen u &lt; 1% bolesnika koji su primali dabrafenib kao monoterapiju i u kombinaciji s trametinibom.
Pancreatitis has been reported to occur at a frequency of ≥ 1/100 to &lt; 1/10 (“common”) in patients treated for inflammatory bowel disease.
Učestalost pankreatitisa u bolesnika liječenih zbog upalne bolesti crijeva bila je od ≥ 1/100 do &lt; 1/10 („često“).
Pancreatitis was reported in &lt; 1% of patients in combination therapy studies with Zerit.
Pankreatitis je bio zabilježen u &lt; 1% bolesnika u ispitivanjima kombinirane terapije s lijekom Zerit.
Pancreatitis was reported in &lt; 1% of patients in combination therapy studies with Zerit.
Pankreatitis je bio zabilježen u &lt; 1% bolesnika u ispitivanjima kombinirane terapije sa lijekomZerit.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING BOX OF 1 BOTTLE, 5 ml &amp; 10 ml.
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA S 1 BOČICOM, 5 ml i 10 ml.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (SINGLE PACK &amp; MULTIPACK ONLY)
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA (SAMO POJEDINAČNO PAKIRANJE I VIŠESTRUKO PAKIRANJE)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (SINGLE PACKS &amp; MULTIPACK ONLY)
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA (SAMO POJEDINAČNA PAKIRANJA I VIŠESTRUKO PAKIRANJE)
Passage of HIV-1 (HXB2) in the presence of increasing 3TC concentrations results in high-level ( &gt; 100 to &gt; 500-fold) lamivudine-resistant viruses and the RT M184I or V mutation is rapidly selected.
Prolaz HIV-1 (HXB2) kroz postupno povećavanu 3TC koncentraciju rezultiralo je virusima koji su rezistentni na lamivudin u visokoj razini ( &gt; 100 do &gt; 500-puta) s brzim odabirom mutacije RT M184I ili V mutacije.
Patient frequencies are defined as: very common ≥1/10; common ≥1/100 to &lt; 1/10; uncommon ≥1/1,000 to
Učestalost nuspojava definirana je kao: vrlo često ≥1/10, često ≥1/100 i &lt; 1/10, manje često ≥1/1000 i
Patient-reported benefits were observed with ranibizumab treatment arms over vPDT (p-value &lt; 0.05) in terms of improvement in the composite score and several subscales (general vision, near activities, mental health and dependency) of the NEI VFQ-25.
Koristi koje su prijavili bolesnici bile su uočene u skupinama koje su primale terapiju ranibizumabom u odnosu na vPDT (p-vrijednost &lt; 0,05) u smislu poboljšanja kompozitnog rezultata i na nekoliko podljestvica (opći vid, aktivnosti koje zahtijevaju vid na blizinu, duševno zdravlje i ovisnost) upitnika VFQ-25 Nacionalnog očnog instituta.
Patient-reported outcomes were evaluated as an exploratory endpoint using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and its associated head and neck cancer specific module (H &amp; N35).
Ishodi prijavljeni od strane bolesnika bili su procijenjeni kao eksploratorna mjera ishoda koristeći osnovni upitnik Europske organizacije za istraživanje i liječenje raka o kvaliteti života (EORTC QLQ-C30) i s njim povezan specifičan modul za rak glave i vrata (H &amp; N35).
Patients (%) achieving HbA1c &lt; 7 %
Bolesnici (%) koji su postigli HbA1c ≤ 7
Patients (%) Achieving HbA1c &lt; 7%
Bolesnici (%) koji su postigli HbA1c &lt; 7
Patients (%) achieving HbA1c &lt; 7%
Bolesnici (%) koji su postigli HbA1c &lt; 7
Patients (%) achieving HbA1c &lt; 7% with baseline HbA1c ≥7% at week 52
Bolesnici (%) s postignutim HbA1c &lt; 7% s početnom vrijednošću HbA1c ≥7% u 52. tjednu
Patients (%) achieving HbA1c &lt; 7% with baseline HbA1c ≥7% at week 52b, 2
Bolesnici (%) s postignutim HbA1c &lt; 7 % s početnom vrijednošću HbA1c ≥ 7 % u 52. tjednub, 2
Patients (%) achieving HbA1c &lt; 7% with baseline HbA1c ≥7%2
Bolesnici (%) s postignutim HbA1c &lt; 7 % s početnom vrijednošću HbA1c ≥ 7 %2
Patients (%) achieving HbA1c &lt; 7% with baseline HbA1c ≥7%2
Bolesnici (%) s postignutim HbA1c &lt; 7% s početnom vrijednošću HbA1c ≥7%2
Patients (%) achieving HbA1c &lt; 7% with baseline HbA1c ≥7%2
Bolesnici (%) s postignutim HbA1c &lt; 7% s početnom vrijednošćuHbA1c ≥7%2
Patients (%) achieving HbA1c &lt; 7.0%
Bolesnici (%) koji su postigli HbA1c &lt; 7,0
Patients (treated with or without MTX) were randomised (tocilizumab:placebo = 2:1) to one of two treatment groups, 75 patients received tocilizumab infusions every two weeks, either 8 mg/kg for patients ≥ 30 kg or 12 mg/kg for patients &lt; 30 kg and 37 patients were assigned to receiving placebo infusions every two weeks.
Bolesnici (liječeni u kombinaciji s MTX-om ili bez njega) su randomizirani u jednu od dvije skupine (tocilizumab:placebo = 2 : 1), pri čemu je 75 bolesnika svaka dva tjedna primalo infuzije tocilizumaba u dozi od 8 mg/kg za bolesnike ≥ 30 kg ili 12 mg/kg za bolesnike &lt; 30 kg, a 37 bolesnika primalo je svaka dva tjedna infuzije placeba.
Patients (≥ 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients &lt; 65 years old.
Bolesnici (≥ 65 godina starosti) sa šećernom bolešću tipa 2 smatraju se podložnijima epizodama hipoglikemije nego bolesnici &lt; 65 godina starosti.
Patients &lt; 12 years of age
Bolesnici u dobi &lt; 12 godina
Patients &lt; 30 kg were randomized 1:1 to receive either tocilizumab 8 mg/kg or 10 mg/kg IV every 4 weeks for 4 doses.
Bolesnici tjelesne težine &lt; 30 kg randomizirani su u omjeru 1:1 u skupinu koja je primala intravenski tocilizumab u dozi od 8 mg/kg ili 10 mg/kg svaka 4 tjedna tijekom 4 doze.
Patients &lt; 6 years of age may need higher doses for maintenance of haemoglobin than patients above that age.
Bolesnici mlađi od 6 godina bi mogli bi trebati veće doze za održavanje hemoglobina od bolesnika starijih od 6 godina.
Patients &lt; 60 kg
Bolesnici tjelesne težine &lt; 60 kg
Patients &lt; 18 years of age:
Bolesnici mlađi od 18 godina:
Patients &lt; 30 kg also receiving valproate medication:
Bolesnici s tjelesnom težinom &lt; 30 kg koji primaju i lijek valproat:
Patients &lt; 30 kg also receiving valproate:
Bolesnici s tjelesnom težinom &lt; 30 kg koji primaju i valproat:
Patients &lt; 30 kg not receiving valproate:
Bolesnici s tjelesnom težinom &lt; 30 kg koji ne primaju valproat:
Patients &gt; 100 kg: 30 ml of BRINAVESS 20 mg/ml is added to 120 ml of diluent.
Bolesnici &gt; 100 kg: 30 ml lijeka BRINAVESS 20 mg/ml dodaje se u 120 ml otopine za razrjeđivanje.
Patients &gt; 75 years of age started treatment with 20 mg dexamethasone.
Bolesnici u dobi od &gt; 75 godina počeli su liječenje dozom od 20 mg deksametazona.
Patients &gt; 70 years may experience more gastrointestinal effects when treated with liraglutide.
Bolesnici u dobi &gt; 70 godina mogu imati više gastrointestinalnih učinaka uz liječenje liraglutidom.
Patients &gt; 75 years received a dexamethasone dose of 20 mg once daily on Days 1, 8, 15, and 22 of each 28-day cycle.
Bolesnici u dobi &gt; 75 godina primali su deksametazon u dozi od 20 mg jednom dnevno 1., 8., 15. i 22. dana svakog 28-dnevnog ciklusa.
Patients achieving target platelet counts &amp; initiating antiviral therapy c
Bolesnici koji su dostigli ciljni broj trombocita i započeli antivirusno liječenje c
Patients aged &lt; 12 years old: Based on results from a clinical trial in which paediatric patients under 12 years of age were shown to have lower exposure of VWF, a prophylactic dose range of 40 – 80 IU VWF:RCo/kg body weight 1 to 3 times a week should be considered. (see Section 5.2).
Bolesnici u dobi &lt; 12 godina: Prema rezultatima kliničkog ispitivanja u kojem su pedijatrijski bolesnici u dobi mlađoj od 12 godina ispoljili niže razine VWF, potrebno je razmotriti raspon doze od 40 – 80 IU VWF:RCo/kg tjelesne težine 1 do 3 puta tjedno (vidjeti dio 5.2).
Patients aged &lt; 12 years old: Based on results from a clinical trial in which paediatric patients under 12 years of age were shown to have lower exposure of VWF, a prophylactic dose range of 40 – 80 IU VWF:RCo/kg body weight 1 to 3 times a week should be considered. (see Section 5.2).
Bolesnici u dobi &lt; 12 godina: Prema rezultatima kliničkog ispitivanja u kojem su pedijatrijski bolesnici u dobi mlađoj od 12 godina ispoljili niže razine VWF, potrebno je uzeti u obzir raspon doze od 40 – 80 IU VWF:RCo/kg tjelesne težine 1 do 3 puta tjedno (vidi poglavlje 5.2).
Patients aged &gt; 2 months to 2 years of age
Bolesnici u dobi od ˃2 mjeseca do 2 godine
Patients also had plaque psoriasis with a qualifying target lesion  2 cm in diameter.
Bolesnici su također trebali imati plak psorijazu s kožnim promjenama promjera &gt; 2 cm.
Patients also required lower administration of erythropoietin/darbopoietin (10.4 % versus 18.1 %, p &lt; 0.001), G-CSF/GM-CSF (3.1 % versus 6.1 %, p = 0.004), and iron preparations (4.3 % versus 7.0 %, p = 0.021).
U tih je bolesnika također rjeđe trebalo primijeniti eritropoetin/darbepoetin (10,4% naspram 18,1%, p &lt; 0,001), G-CSF/GM-CSF (3,1% naspram 6,1%, p = 0,004) i pripravke željeza (4,3% naspram 7,0%, p = 0,021).
Patients also required lower administration of erythropoietin/darbopoietin (10.4 % versus 18.1 %, p &lt; 0.001), G-CSF/GM-CSF (3.1 % versus 6.1 %, p=0.004), and iron preparations (4.3 % versus 7.0 %, p=0.021).
U tih je bolesnika također rjeđe trebalo primijeniti eritropoetin/darbepoetin (10,4% naspram 18,1%, p &lt; 0,001), G-CSF/GM-CSF (3,1% naspram 6,1%, p = 0,004) i pripravke željeza (4,3% naspram 7,0%, p = 0,021).
Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p &lt; 0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p = 0.004), and iron preparations (4.3% versus 7.0%, p = 0.021).
U tih je bolesnika također rjeđe trebalo primijeniti eritropoetin/darbepoetin (10,4% naspram 18,1%, p &lt; 0,001), G-CSF/GM-CSF (3,1% naspram 6,1%, p = 0,004) i pripravke željeza (4,3% naspram 7,0%, p = 0,021).
Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p &lt; 0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p=0.004), and iron preparations (4.3% versus 7.0%, p=0.021).
U tih je bolesnika također rjeđe trebalo primijeniti eritropoetin/darbepoetin (10,4% naspram 18,1%, p &lt; 0,001), G-CSF/GM-CSF (3,1% naspram 6,1%, p = 0,004) i pripravke željeza (4,3% naspram 7,0%, p = 0,021).
Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p &lt; 0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p=0.004), and iron preparations (4.3% versus 7.0%, p=0.021).
U tih je bolesnika također rjeđe trebalo primijeniti eritropoetin/darbepoetin (10,4% naspram 18,1%, p &lt; 0,001), G-CSF/GM-CSF (3,1% naspram 6,1%, p=0,004) i pripravke željeza (4,3% naspram 7,0%, p=0,021).
Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p &lt; 0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p=0.004), and iron preparations (4.3% versus 7.0%, p=0.021).
U tih je bolesnika također rjeđe trebalo primijeniti eritropoetin/darbopoetin (10,4% naspram 18,1%, p &lt; 0,001), G-CSF/GM-CSF (3,1% naspram 6,1%, p = 0,004) i pripravke željeza (4,3% naspram 7,0%, p = 0,021).
Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI &gt; 30 kg/m2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.
Rizični bolesnici (glukoza natašte 5,6 do 6,9 mmol/l, BMI &gt; 30 kg/m2, povišeni trigliceridi, hipertenzija) moraju biti praćeni klinički i biokemijski prema nacionalnim smjernicama.
Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI &gt; 30kg/m 2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.
Rizične bolesnike (glukoza natašte 5,6 do 6,9 mmol/l, BMI &gt; 30kg/m2, povišeni trigliceridi, hipertenzija) treba pratiti klinički i laboratorijski prema nacionalnim smjernicama.
Patients carrying the SLCO1B1 gene allele (c.521T &gt; C) coding for a less active OATP1B1 protein have an increased systemic exposure of simvastatin and increased risk of myopathy.
Bolesnici koji su nositelji alela (c.521T &gt; C) gena SLCO1B1, koji kodira manje aktivni protein OATP1B1, imaju povećanu sistemsku izloženost simvastatinu i povećani rizik od miopatije.
Patients categorised as non-YMDD mutant were those with &gt; 95 % wild-type HBV at all annual time-points during the 5-year study period 2 Upper limit of normal
Bolesnici bez YMDD tipa virusa definirani su kao oni koji su imali &gt; 95% divlji tip HBV-a na svakom godišnjem mjerenju tijekom petogodišnjeg razdoblja gornja granica normale
Patients could be enrolled only if they had experienced cardiac ischemia at rest ( 10 minutes) within the previous 24 hours and had: either ST-segment changes: ST depression &gt; 0.5 mm of less than 30 minutes or persistent ST elevation &gt; 0.5 mm not requiring reperfusion therapy or thrombolytic agents, T-wave inversion ( &gt; 1 mm), or increased CK-MB.
Bolesnici su mogli biti uključeni samo ako su u prethodna 24 sata imali srčanu ishemiju u mirovanju (≥ 10 minuta) i jedno od sljedećeg: promjene ST-segmenta: depresiju ST segmenta &gt; 0,5 mm u trajanju manjem od 30 minuta ili trajnu ST elevaciju &gt; 0,5 mm koja ne zahtijeva reperfuzijsku terapiju ili trombolitike, inverziju T-vala ( &gt; 1 mm) ili povišeni CK-MB.
Patients currently on methotrexate therapy (stable for  2 months) could continue at a stable dose of  25 mg/week methotrexate.
Bolesnici koji su u tom trenutku primali metotreksat (stabilni &gt; 2 mjeseca) mogli su nastaviti s njegovom primjenom u stalnoj dozi od &lt; 25 mg tjedno.
Patients demonstrating a subsequent increase in QT-interval to &gt; 480 msec or prolongation over pre-treatment by &gt; 20 msec should discontinue ritonavir-boosted Invirase.
Bolesnici u kojih se utvrdi naknadno produljenje QT-intervala na &gt; 480 ms ili produljenje u odnosu na početne vrijednosti za &gt; 20 ms trebaju prestati uzimati Invirase pojačan ritonavirom.
Patients enrolled were aged 2 to &lt; 20 years (mean age of 8.5 years and mean disease duration of 3.5 years at baseline) and had active disease defined as ≥ 2 joints with active arthritis, fever and elevated CRP.
Uključeni bolesnici bili su u dobi od 2 do &lt; 20 godine (srednja dob od 8,5 godina i srednje trajanje bolesti 3,5 godine na početku) te imali aktivnu bolest definiranu kao ≥ 2 zgloba s aktivnim artritisom, vrućicom i povišenim CRP-om.
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p &lt; 0.0001 for all).
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post-hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđen u 24. tjednu (36%, p = 0,0459), i MR ishode (nove/povećane T2 60%, Gd+ 71%, i nove T1 hipointenzivne lezije 53%; p &lt; 0,0001 za sve.)
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p &lt; 0.0001 for all).
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post-hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđen u 24. tjednu (36%, p = 0,0459), i MR ishode (nove/povećanje T2 60%, Gd+ 71%, i nove T1 hipointenzivne lezije 53%; p &lt; 0,0001 za sve.)